2026 · Neurology
Association Between Menopausal Hormone Therapy and Alzheimer Disease Neuropathology
Verdict
UNSCIENTIFIC
The study only partly follows the scientific method inside its paradigm, and the paradigm itself does not pass. The worse layer decides. The verdict is unscientific.
1·Study methodology · inside the paradigm
MIXED
Partly follows the scientific method within Amyloid Hypothesis / Alzheimer's Disease Model.
2·Paradigm · Amyloid Hypothesis / Alzheimer's Disease Model
UNSCIENTIFIC
Fails the tests. The worse layer decides.
How the verdict is decided
The verdict grades both layers: the paradigm this study assumes, and how the study was carried out inside it. Both must be scientific for the whole thing to be scientific. A clean method inside an unscientific paradigm is unscientific. An unscientific method inside a better paradigm is unscientific. A split on either layer is mixed. The worse layer decides.
1·Study methodology
Did this study test its claim with methods that are independent, falsifiable, and non-circular?
MIXED
This study claims that estrogen-only menopausal hormone therapy is associated with reduced Alzheimer disease pathology on autopsy, lower amyloid biomarker levels in plasma and CSF, and lower odds of clinical dementia diagnoses. The tests split.
Independently Verifiable
Fail
Every outcome in this study is a classification the Alzheimer's model assigns to tissue or fluid, not something a stranger could witness without accepting that model first.
Falsifiable
Pass
The groups were defined by self-reported drug use, and the comparison could have shown no difference or the opposite association.
Non-Circular
Fail
The autopsy criteria and amyloid assays that define the outcomes were built from the same Alzheimer's model the study uses to interpret its results.
Why
The study compared women who reported taking estrogen-only hormone therapy to women who did not. That part is visible. But every outcome they measured required the Alzheimer's model to produce a number. The primary outcome was AD pathology on autopsy. An autopsy opens a brain. What you physically see is tissue. What the model tells you is AD pathology. The secondary outcomes were amyloid levels in blood and spinal fluid. Machines produced signals, and the model said those signals were amyloid. The clinical outcomes were dementia diagnoses, which require diagnostic criteria from the medical framework. A stranger who rejects the AD model could see that some women took hormones and some did not, and that some died. They could not see AD pathology or amyloid load without the model telling them what those signals meant. The groups were defined honestly by self-reported drug use, so the comparison could have gone either way. But the outcomes are classifications the model produces, and the instruments that generate them were built from the model they claim to validate.
2·Paradigm · Amyloid Hypothesis / Alzheimer's Disease Model
Does the framework this study assumes pass the three tests?
UNSCIENTIFIC
Independently Verifiable
Fail
What the model calls amyloid has never been observed without first accepting the model and its staining or assay protocols.
Falsifiable
Fail
When drugs that lower amyloid failed to improve cognition, the field called the timing wrong rather than calling the hypothesis wrong.
Non-Circular
Fail
The assays that detect amyloid were designed from the amyloid hypothesis, so they find what the hypothesis already named.
Why
The amyloid hypothesis claims that amyloid plaques accumulate in brains and cause Alzheimer's disease. Nobody has seen these plaques without the model's staining protocols and classification criteria. The instruments produce signals. The model says the signals are amyloid. When drugs that lower amyloid failed to help patients think, the field did not abandon the hypothesis. They said the treatment came too late, or the patient was too far gone, or another mechanism was involved. The hypothesis has an escape hatch for every failure. The assays were built to find what the hypothesis already named, so they find it, and the field calls that confirmation. The model treats a tagged signal as the disease instead of asking what damaged the patient's brain.
From the study
The odds of increased AD pathology on autopsy (primary outcome) were significantly decreased in MHT users relative to nonusers (odds ratio [OR] 0.65, 95% CI 0.48-0.88, p = 0.005).
MHT use was associated with secondary outcomes including significantly decreased amyloid pathologic load assessed through plasma (β = 0.44, 95% CI 0.16-0.73, p = 0.0025) and CSF (β = 0.07, 95% CI 0.002-0.13, p = 0.030).
We sought to examine the associations between MHT use and neuropathologic, clinical, and imaging/fluid biomarker outcomes.